Burford Insights: What's ahead for pharma and biotech litigation?
The pharmaceutical and biotechnology sectors were dominated by the Covid-19 pandemic in 2020, which promoted a surge of research and business activity. But with multiple vaccines in circulation, biopharma is an area to watch in the coming year.
Burford's Joshua Harris, Vice President with responsibility for assessing and underwriting legal risk, focusing on patent and intellectual property matters, has been consecutively named as one of the world's leading IP strategists by the IAM Strategy 300. In this video, he explains what's ahead for pharma and biotech litigation:
- The major trends and developments in the pharmaceutical and biotech sectors in 2020
- The impact of the Covid-19 pandemic on drug development pipelines
- The implications for the patent sector as we move in 2021 and beyond
This video was recorded on 21 January 2021.
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any ordinary shares or other securities of Burford. This video may not be copied, distributed, published or reproduced, in whole or in part.